Preclinical efficacy of [V 4 Q 5 ]dDAVP, a second generation vasopressin analog, on metastatic spread and tumor-associated angiogenesis in colorectal cancer by Garona, Juan et al.
Cancer Res Treat. 2018 Jun 1 [Epub ahead of print] 
pISSN 1598-2998, eISSN 2005-9256
https://doi.org/10.4143/crt.2018.040
│ http://www.e-crt.org │ 1Copyright ⓒ 2018 by  the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Open Access
Preclinical Efficacy of [V4Q5]dDAVP, a Second Generation Vasopressin
Analog, on Metastatic Spread and Tumor-Associated Angiogenesis 
in Colorectal Cancer
Original Article
Purpose
Control of metastatic spread of colorectal cancer (CRC) remains as a major therapeutic
challenge. [V4Q5]dDAVP is a vasopressin peptide analog with previously reported anticancer
activity against carcinoma tumors. By acting as a selective agonist of arginine vasopressin
type 2 membrane receptor (AVPR2) present in endothelial and tumor cells, [V4Q5]dDAVP is
able to impair tumor aggressiveness and distant spread. Our aim was to evaluate the 
potential therapeutic benefits of [V4Q5]dDAVP on highly aggressive CRC disease using ex-
perimental models with translational relevance.
Materials and Methods
Murine CT-26 and human Colo-205 AVPR2-expressing CRC cell lines were used to test the
preclinical efficacy of [V4Q5]dDAVP, both in vitro and in vivo.
Results
In syngeneic mice surgically implanted with CT-26 cells in the spleen, sustained intravenous
treatment with [V4Q5]dDAVP (0.3 µg/kg) dramatically impaired metastatic progression to
liver without overt signs of toxicity, and also reduced experimental lung colonization. The
compound inhibited in vivo angiogenesis driven by Colo-205 cells in athymic mice, as well
as in vitro endothelial cell migration and capillary tube formation. [V4Q5]dDAVP exerted
AVPR2-dependent cytostatic activity in vitro (IC50 1.08 µM) and addition to 5-fluorouracil 
resulted in synergistic antiproliferative effects both in CT-26 and Colo-205 cells.
Conclusion
The present preclinical study establishes for the first time the efficacy of [V4Q5]dDAVP on
CRC. These encouraging results suggest that the novel second generation vasopressin ana-
log could be used for the management of aggressive CRC as an adjuvant agent during sur-
gery or to complement standard chemotherapy, limiting tumor angiogenesis and metastasis
and thus protecting the patient from CRC recurrence.
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Introduction
With an annual incidence of approximately 1 million cases
and a mortality of more than 500,000 patients per year, col-
orectal cancer (CRC) represents a central public health con-
cern worldwide [1]. In particular, metastatic CRC disease is
still associated with a poor prognosis and a high mortality
rate, mainly due to hepatic and lung secondary lesions and
limitations in the standard therapies. In this clinical setting
the overall median survival is 24 months and only 10% of the
patients survive more than 5 years. Taken altogether, there
is a clear need to develop novel therapeutic strategies to 
improve the survival of advanced or recurrent CRC patients.  
Our group was the first to report the antimetastatic and
angiostatic  activity of the hemostatic drug desmopressin 
(1-deamino-8-D-arginine vasopressin; dDAVP) as part of a
drug repurposing program in oncology [2,3]. dDAVP is a
first generation synthetic derivative of vasopressin (AVP),
that acts as a selective agonist on arginine vasopressin type
2 membrane receptor (AVPR2) present in microvascular 
endothelial cells [4] and several human tumor cell lines, 
including breast, prostate, lung cancer, and CRC [3,5,6]. After
AVPR2 agonistic stimulation in endothelium, dDAVP indu-
ces an acute release of von Willebrand factor, an hemostatic
[4] and pro-apoptotic glycoprotein known to inhibit metasta-
tic spread of malignant cells [7,8], recruit leukocytes [9], and
cause vascular normalization [10]. By acting directly on can-
cer cells, dDAVP also triggers antiproliferative signalling
pathways and favors the formation of angiostatin (ANG), a
potent inhibitor of angiogenesis that is generated by cancer-
mediated proteolysis of plasminogen [3]. Due to its safe 
hemostatic profile and anticancer effects, dDAVP has been
evaluated as a perioperative adjunctive therapy in a phase II
dose-escalation trial in patients with breast cancer (NCT-
01606072) [11] and is currently being evaluated in a phase II
trial exploring safety, tolerability, and symptom control in
CRC patients with rectal bleeding (NCT01623206). Consid-
ering its selective effects on AVPR2-expressing malignant
and vascular tissue, dDAVP appears as a promising lead
compound for the development of novel peptide analogs
with enhanced anticancer efficacy. Lead drug dDAVP was
rationally modified after conducting structure-activity stud-
ies using alanine-scanning  to determine key aminoacidic 
positions for its biological activity. As a result of this struc-
ture-based drug derivatization novel peptidic analog [V4Q5]
dDAVP (1-deamino-4-valine-5-glutamine-8-D-arginine vaso-
pressin) was developed. [V4Q5]dDAVP was selected from a
wide panel of dDAVP analogs with different sequence and
structural modifications, mainly aimed at the N-terminal
loop of the molecule, which has a key role in ligand-receptor
interaction and antitumor activity [12-14]. Novel compound
was evaluated in highly aggressive breast, lung and prostate
cancer preclinical models, deploying enhanced cytostatic, 
antimetastatic and angiostatic effects in comparison to
parental peptide dDAVP [5,15,16]. Interestingly, [V4Q5]
dDAVP direct cytostatic effects on tumor cells were associ-
ated to AVPR2 specific signaling pathways, G0/G1 phase
cell cycle arrest and activation of adenylate cyclase/cAMP/
protein kinase A (PKA) axis. Acute toxicology studies were
also conducted in different animal models, suggesting that
intravenous administration of [V4Q5]dDAVP is safe at doses
at least 300-fold above than required for antiangiogenic/
antimetastatic effects [15].
Monstein et al. [17] presented a complete characterization
of vasopressin receptor expression in the human gastroin-
testinal tract and surrounding tissues. They demonstrated
that AVPR2 is widely expressed in normal and malignant
biopsy samples from colon, rectum, ileum, duodenum, stom-
ach, esophagus and gallbladder. Additionally, 7 years ago
our group reported for the first time AVPR2 expression in
human Colo-205 and murine CT-26 CRC cell lines [6]. 
Unfortunately, as occurs in many types of cancers, CRC
patients are diagnosed once the disease is at an advanced
stage. In this clinical scenario therapy includes combined 
administration of several cytotoxic agents such as 5-fluo-
rouracil (5-FU) in addition to surgery or radiotherapy [18].
Despite the significant improvement in CRC management,
the efficacy of current treatment schemes is reduced due to
lack of selectivity, high associated toxicity and development
of resistance mechanisms. This demands the development of
alternative therapeutic strategies with novel molecular tar-
gets involved in CRC progression. 
The current study aimed at testing the use of vasopressin
analog [V4Q5]dDAVP on highly aggressive CRC experimen-
tal models, in order to evaluate its preclinical anticancer 
efficacy with particular interest in key pathological processes
related to disease progression such as metastatic spread to
liver and lung, cellular growth and angiogenesis induction.
Potential therapeutic benefits of [V4Q5]dDAVP addition to
standard-of-care chemotherapy were also explored in vitro.
Materials and Methods
1. Drugs 
[V4Q5]dDAVP was obtained from Romikin S.A. (member
of CHEMO group, Argentina) following GMP standards or
purchased from American Peptide Company Inc. (member
of BACHEM group, Torrence, CA). Product and lot number:
369184 and 1507008T, respectively). Peptide purity was 
98%-99% as assesed by high-performance liquid chromatog-
raphy-mass spectrometry. Peptide sequence is as follows:
Mpr-Tyr-Phe-Val-Gln-Cys-Pro-DArg-Gly-NH2 (disulfide bri-
dge between Mpr-Cys). In order to achieve work concentra-
tions, [V4Q5] dDAVP was diluted in physiological saline
solution. The chemotherapeutic drug 5-FU was provided by
Bristol-Myers Squibb (Princeton, NJ).
2. Tumor cell lines and culture conditions
CT-26 (ATCC CRL-2638) and Colo-205 (ATCC CCL-222)
cancer cell lines were obtained from the American Type Cul-
ture Collection. CT-26 is a highly aggressive and metastatic
KRAS-mutated murine colon carcinoma [19]. Colo-205 is a
human colon adenocarcinoma cell line bearing the BRAF
(V600E) mutation [20]. Colo-205 cells grow as mixed, adher-
ent and suspension cultures. Tumor cell lines were grown in
RPMI (Gibco, Rockville, MD) plus 10% fetal bovine serum
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(FBS), 2 mM glutamine and 80 μg/mL gentamycin, at 37°C
in a humidified atmosphere of 5% CO2. HMVEC-L human
microvascular endothelial cell line was obtained from Cas-
cade Biologics and cultured in gelatin coated plates using 
endothelial cell medium with specific growth factors (EGM-
2 MV Bullet Kit, Lonza, Milano, Italy). All cells were har-
vested using a tripsin/EDTA solution (Gibco) diluted in
phosphate buffered saline.
3. Animals
Inbred immunocompetent female BALB/c AnN and out-
bred athymic female N:NIH(S)-nu mice aged 8 weeks with a
weight of aproximately 30 and 22 g, respectively, were pur-
chased from UNLP (Universidad Nacional de La Plata,
Buenos Aires, Argentina), and, after randomization, housed
at five mice per cage in our animal house facility at the 
National University of Quilmes. Food and water were pro-
vided ad libitum and general health status of the animals was
monitored daily. 
4. Murine colorectal tumor model of hepatic metastases
To evaluate the impact of [V4Q5]dDAVP sustained treat-
ment on colorectal tumor progression and metastatic spread
to liver a mixture containing 1.5×104 CT-26 CRC cells and
serum-free growth medium was surgically injected in the
spleen of syngeneic BALB/c mice. For splenic inoculation,
mice were anesthetized, followed by left upper quadrant 
laparotomy and splenic exteriorization. Animals were mon-
itored for water consumption, weight and general behavioral
status, and sacrificed by cervical dislocation 21 days after 
CT-26 inoculation. [V4Q5]dDAVP peptide was injected at a
dose of 0.3 μg/kg intravenously, being a clinically relevant
dose with widely acknowledged antitumor properties in
mice [15], 30 minutes before tumor cell injection, and contin-
ued on a three times a week basis until the end of the proto-
col. This specific treatment schedule was chosen given that
peptides such as [V4Q5]dDAVP, or its parental compound
dDAVP, can induce tachyphylaxis with daily applications.
To investigate the presence of metastases, liver, intestines,
and spleen were removed, weighted and fixed in buffered
formalin after animals were sacrificed. Surface hepatic nod-
ules were counted under a dissecting microscope, and 
lesions were further confirmed by histopathology.
5. Murine colorectal tumor model of experimental metas-
tases to lung
To evaluate [V4Q5]dDAVP effect on blood-borne experi-
mental metastases, 2×105 CT-26 cells in serum-free growth
medium were injected into the tail vein of mice [15]. On day
21, colonized lungs were excised, weighted, fixed in Bouin´s
solution and photographed. Pulmonary lesions and differ-
ences between experimental groups were further confirmed
by histopathology. [V4Q5]dDAVP was administered using
two 0.3 μg/kg intravenous doses, the first at time zero and
the second 24 hours after tumor cell injection.
6. In vivo angiogenesis assay
To evaluate the effects on CRC-induced angiogenesis, a
modified Matrigel plug assay was conducted. A mixture con-
taining 500 μL of Matrigel, heparin (50 U/mL) and 2.5×106
Colo-205 tumor cells in 100 μL serum-free growth medium
was injected subcutaneously into athymic mice. Treatment
consisted of three weekly intravenous doses of [V4Q5]dDAVP
of 0.3 μg/kg. Animals were sacrificed 14 days after cell injec-
tion. Plugs were recovered and scanned at high resolution.
The extent of vascularization was assessed by the amount of
hemoglobin detected in the implants using the Drabkin
method (Sigma-Aldrich, St. Louis, MO). The mean optical
density of plugs from control group was taken as 1 (relative
hemoglobin content). 
7. In vitro angiogenesis assays
[V4Q5]dDAVP capacity to modulate microvascular endo-
thelial cell morphogenesis and migration was evaluated. In
vitro endothelial cell morphogenesis assay was performed
using Matrigel-coated 24-well plates (BD Biosciences, San
Jose, CA) [3]. Briefly, 1×105 AVPR2-positive HMVEC-L cells
were incubated with [V4Q5]dDAVP (1 μM) and,  after allow-
ing capillary tube formation for 24 hours, randomly chosen
fields were photographed at ×100 magnification and quan-
tification was conducted. The number of capillary-like tubes
formed in control cultures was taken as 100%. Direct effect
of [V4Q5]dDAVP on endothelial cell migration was evaluated
using the Transwell migration assay using a modified Boy-
den chamber inserted with polyethylene terephthalate filter
membrane containing 8-μm pores in 24-well plates (Greiner
Bio-One, Monroe, NC). 1×105 HMVEC-L cells suspended in
300 μL of serum-free medium were seeded onto the upper
compartment of the Transwell chamber. The lower chamber
was filled with medium containing FBS as chemoattractant
and [V4Q5]dDAVP using a final concentration of 1 μM. After
incubation for 24 hours the medium in the upper chamber
was removed and the filters were fixed with crystal violet
0.5% and MeOH 20% for 10 minutes. The cells remaining on
the upper surface of the filter membrane were then com-
pletely removed by wiping with a cotton swab. The migrated
cells were counted from five randomly selected fields (×200
magnification) under an inverted microscope.
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8. AVPR2 expression analysis by quantitative real time
polymerase chain reaction 
Total RNA from 1×106 Colo-205, MCF-7, or H125 cells was
purified with Trizol. RNA was reverse transcribed with 
SuperScript III first-Strand (Thermo Fisher Scientific Inc.,
Waltham, MA) according to the manufacturer's protocol. The
following specific forward and reverse primers were used:
for AVPR2, 5′-CTGGCCAAGGACACTTCATC-3′ and 5′-
GAAGGCAGCTGAGCTTC-3′; for hypoxanthine phospho-
ribosyl transferase 1 (HPRT1), 5´-AACGTCTTGCTCGAG-
ATGTG-3´ and 5′-GCTTTGATGTAATCCAGCAGG-3´. Qua-
ntitative real time polymerase chain reaction was performed
using SYBR Green PCR Master Mix (Thermo Fisher Scientific
Inc.) and StepOne Real-Time PCR System (Applied Biosys-
tems, Foster City, CA). The following thermal cycling condi-
tions were used: 48°C for 30 minutes, 95°C for 10 minutes,
40 cycles of 95°C for 15 seconds followed by 60°C for 60 sec-
onds. Each sample was analyzed in triplicate and mean cycle
threshold values (Ct) were used for further analysis. Ct val-
ues were normalized for HPRT1 expression levels and nor-
malized to control samples. Relative quantification values
were calculated as 2(-ΔΔCt).
9. Clonogenic assay
In vitro experiments were performed using nanomolar and
low micromolar concentrations of the peptide, a range con-
sistent with the in vivo dosage, as reported [5,15,16]. Colony
forming ability was examined by the 2D clonogenic assay for
adherent murine CRC cells. CT-26 cells were grown in com-
plete medium with [V4Q5]dDAVP (0.1-1.5 μM) and after 72
hours, medium with tested compound was renewed. Seven
days after cell seeding, clonogenic cultures were fixed and
stained with crystal violet, and colonies of more than 50
tumor cells were counted.
10. Cell proliferation
Antiproliferative effect against rapidly growing tumor
cells was measured using the MTT and MTS assays (Sigma-
Aldrich) for high density adherent or non adherent cell cul-
tures, respectively. Briefly, cells were plated in 96-well flat
bottom plates at a density of 2.5×103 per 200 μL in complete
RPMI medium, allowed to attach overnight, and then treated
for 72 hours with tested compounds. Following previously
published protocols, in order to calculate the 50% inhibitory
concentrations (IC50) colorectal cells were treated using 
micromolar concentrations of 5-FU (0.1-5 or 1-500 μM for 
CT-26 or Colo-205 cells, respectively) [6]. Combination stud-
ies using [V4Q5]dDAVP (1 μM) plus sub-IC50 of 5-FU (250-500
nM or 2.5-5 μM, depending on cell type), were also con-
ducted. MTT or MTS reagent was added to each well and the
plate incubated for 4 hours. In the case of MTT, after solubil-
isation of formazan crystals by using dimethyl sulfoxide the
absorbance of each well was measured at 570 nm. In the case
of MTS, direct measurement of absorbance at 490 nm was
conducted. The optical density of untreated control cells was
taken as 100% viability.
11. Statistics
All statistical analyses were performed using the PRISM 6
GraphPad Software Inc. (La Jolla, CA) or Compusyn soft-
ware (ComboSyn Inc., Paramus, NJ). To compare differences
between two experimental groups two-tailed Mann Whitney
or t tests were used for non-parametric or normal distribu-
tion of data, repectively. In case of more than two experimen-
tal groups, ANOVA analysis with Tukey's multiple compa-
risons post-test was used. Kruskal-Wallis analysis with
Dunn's multiple comparisons post-test was used in case of
non-parametric distribution of data. In tumor progression
protocols, growth rates represent the slopes of the linear 
regressions of the tumor volumes over time. In combina-
tional studies sinergy was determined when combinational
index (CI) was < 1. Differences were considered statistically
significant at a level of p < 0.05. Data were presented as 
median with range (non parametric) or mean±standard 
deviation or standard error of mean (parametric).
12. Ethical statement
All animal protocols have been carried out in accordance
with the Guide for the Care and Use of Laboratory Animals
as adopted by the U.S. National Institutes of Health and were
approved by our institutional Animal Care Committee
UNQUI-CICUAL (Resolution CD CyT Nº075/14).
Results
1. [V4Q5]dDAVP treatment inhibits CRC liver metastases
Liver metastases is the leading direct cause of cancer-
related deaths in CRC [21,22]. Taking this clinical concern
into account we first evaluated the impact of [V4Q5]dDAVP
treatment on metastatic spread to liver in animals surgically
implanted in the spleen with CT-26 cells (Fig. 1). All animals
from both experimental groups displayed visible liver metas-
tases, with a maximum of 57 macroscopic nodules per mouse
as observed in the control group (Fig. 1B). In this experimen-
tal setting, perioperative plus sustained intravenous admin-
istration of [V4Q5]dDAVP caused a remarkable decrease in
liver metastatic burden. Total liver metastases in [V4Q5]
dDAVP-treated animals was three times lower than control
group with 9 (2-23) versus 31.5 (21-57) nodules in [V4Q5]
dDAVP and saline vehicle groups, respectively (median with
range) (Fig. 1C, left). Moreover, the number of macrometasta-
tic lesions (metastatic nodules larger than 1 mm) drop from
20 (14-33), as found in the control group, to 2.5 (1-12) after
[V4Q5]dDAVP treatment (Fig. 1C, right). Additionally, as
shown in Fig. 1A, some degree of reduction in primary
splenic disease was also observed; however, no statistical sig-
nificance was achieved after analyzing spleen weights (371
mg [146-871] vs. 200 mg [103-436] in control and [V4Q5]
dDAVP groups, respectively). Values expressed as median
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Fig. 1.  Intravenous administration of [V4Q5]dDAVP inhibits metastatic progression of colorectal cancer cells to liver. Mice
were inoculated intrasplenically with 1.5×104 CT-26 colorectal carcinoma cells, and after 21-day hepatic metastases were
evaluated. [V4Q5]dDAVP peptide was injected at a dose of 0.3 μg/kg intravenous 30 minutes before tumor cell injection, and
continued on a three times a week basis until the end of the protocol. (A) Spleens with CT-26 primary tumors from control
or [V4Q5]dDAVP-treated mice after 21 days of tumor cell inoculation. (B) Superficial macroscopic colorectal metastasis in
liver from control (top) or [V4Q5]dDAVP group (bottom) are depicted. (C) Quantification of total (left) or macrometastatic
(> 1 mm of diameter) (right) liver nodules per mice. Metastatic nodules per mouse are expressed as median with range (box
and whiskers). Mice weight is expressed as mean and SD. *p < 0.05 and **p < 0.01, unpaired t test.
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and range (p=0.17). Differences in number and extension of
metastatic lesions can be clearly observed in representative
sections of colonized livers as depicted in Fig. 2. Administra-
tion of [V4Q5]dDAVP in mice was not associated with overt
toxic effects and no significant differences in mouse body
weight were found when compared to the control group
throughout the experiment (S1 Fig.). These results are in con-
cordance with previously reported toxicological and safety
studies, where, after intravenous doses of up to 100 μg/kg
of [V4Q5]dDAVP, no altered biochemical and hematological
parameters or signs of toxicity were observed [15].
2. [V4Q5]dDAVP impairs experimental CRC metastases to
lung 
Given that liver and lungs are the two most frequent sites
of metastatic spread of CRC [21], we further tested the effects
of [V4Q5]dDAVP administration on experimental metastatic
spread to lung of CRC cells in BALB/c mice (Fig. 3). After
analyzing colonized lung weights as a gross measure of
metastatic tumor burden, [V4Q5]dDAVP intravenous treat-
ment given before and after tumor cell injection inhibited
pulmonary metastasis formation by 36% in comparison to
saline vehicle-treated animals (Fig. 3B). Histological assess-
ment of metastatic burden in lungs was also conducted. Mul-
tiple subpleural and intrapulmonary metastatic nodules
were visualized in controls (Fig. 3C). In contrast, lungs from
animals receiving [V4Q5]dDAVP treatment showed a few 
peripheral nodules of small sizes, with a well-conserved pul-
monary parenchyma (Fig. 3C).
3. CRC-induced angiogenesis modulation by [V4Q5]dDAVP
It is well known that high vascular density and overexpres-
sion of pro-angiogenic biomarkers in CRC correlate with dis-
ease progression [23]. In this setting we evaluated the effect
of [V4Q5]dDAVP administration on in vivo angiogenesis 
(Fig. 4) triggered by human AVPR2-expressing CRC cells 
(S2 Fig.) in nude mice. As observed in Fig. 4, 2 weeks of 
intravenous treatment using [V4Q5]dDAVP was capable of
reducing Colo-205 cell-induced angiogenic response by
nearly 60% in contrast with saline vehicle-treated animals
(Fig. 4A and B).
Additionally, direct modulation of AVPR2-expressing 
microvascular cell migration and morphogenesis was asse-
ssed (Fig. 4C and D). After overnight incubation with [V4Q5]
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Fig. 2.  Histopathological assessment of colorectal cancer liver metastatic spread inhibition by [V4Q5]dDAVP. Representative
microphotographs of livers from control (A, B) mice receiving saline solution, and mice treated with [V4Q5]dDAVP (C, D).
Superficial (A, C) and intrahepatic (B, D) metastatic lesions are indicated with “M” in bold (H&E staining, ×40; insets ×200
[magnificated dashed square]). Scale bars=500 μm and 200 μm, respectively. 
Control
[V4Q5]dDAVP
Control
[V4Q5]dDAVP
A B
C D
dDAVP endothelial cell chemotaxis was reduced by 26% ver-
sus control. [V4Q5]dDAVP was also capable of modulating
capillary-like tube formation by microvascular cells, a key
early event in novel vessel development, decreasing mor-
phogenic capacity by 33% (Fig. 4C and D). 
4. Direct cytostatic effects of [V4Q5]dDAVP on CRC cells
and potential benefits after combination with standard
chemotherapy
Growth-modulating activity was evaluated in low and
high density CRC cell cultures exposed to [V4Q5]dDAVP
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Fig. 3.  Reduction of pulmonary experimental metastatic spread of colorectal cancer cells by intravenous administration of
[V4Q5]dDAVP. Mice were inoculated with 2×105 CT-26 colorectal carcinoma cells in the lateral tail vein, and after 21-day
pulmonary metastases were evaluated. [V4Q5]dDAVP peptide was injected at a dose of 0.3 μg/kg intravenous 30 minutes
before tumor cell injection and 24 hours after. (A) Representative left lung lobes (five most colonized lobes from each group)
are depicted. Bouin dye. (B) Weight of colonized lungs from different experimental groups. Lung weights are expressed as 
median with range (box and whiskers). *p < 0.05, unpaired t test. n=12 animals per experimental group. (C) Representative
sections of lungs from control (top) and treated (bottom) animals are depicted (H&E staining, ×40). Scale bars=500 μm.
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(Fig. 5). Long-term in vitro treatment using [V4Q5]dDAVP 
reduced clonogenic growth of highly aggressive CT-26 CRC
cells, obtaining an IC50 of 1.08 μM (Fig. 5A). Impairment of
tumor cell colony formation was completely reverted  after
pre-incubation with the selective AVPR2 antagonist tolvap-
tan (Fig. 5B), hinting a AVPR2-dependency of [V4Q5]dDAVP
in vitro activity. 5-FU is a standard chemotherapy agent
widely used in the treatment of malignancies in the gastroin-
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Fig. 4.  Effect of [V4Q5]dDAVP on colorectal tumor-induced angiogenesis and microvascular cell migration and morphogen-
esis. (A) Colo-205 cell-induced angiogenesis evaluated by a modified-Matrigel plug assay. Representative images of plugs
recovered from vehicle or [V4Q5]dDAVP (0.3 μg/kg intravenously, thrice-weekly for 2 weeks) treated mice are depicted. (B)
Quantitative assessment of angiogenesis was achieved by the determination of relative hemoglobin content in Matrigel plugs
using the Drabkin's method. n=10 animals per experimental group. (C) Quantification of in vitro migration and tube formation
by arginine vasopressin type 2 membrane receptor‒expressing microvascular HMVEC-L cells incubated overnight with
[V4Q5]dDAVP (1 μM) in comparison to saline vehicle. (D) Crystal violet staining of microvascular endothelial cells that
crossed the polycarbonate membrane in the Transwell migration assay (left) and representative images of vasculature-like
structures formed by HMVEC-L cells in the morphogenesis assay (right, ×100). Data are presented as mean±standard error
of mean and are representative of at least two independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control, unpaired
t test.
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Fig. 5.  In vitro direct cytostatic effects of [V4Q5]dDAVP on colorectal cancer (CRC) cells alone or in combination with stan-
dard-of-care chemotherapy. (A) IC50 calculation and reduction of in vitro CT-26 cell colony formation by [V4Q5]dDAVP (right).
Dotted line indicates 50% inhibition. Statistical significance (*p < 0.05) in IC50 calculation studies for [V4Q5]dDAVP was
achieved with drug concentrations ≥ 1 μM. Representative photographs of vehicle- or [V4Q5]dDAVP-treated low density
CT-26 cultures are depicted (left). (B) Reversal of [V4Q5]dDAVP cytostatic effect by addition of arginine vasopressin type 2
membrane receptor selective chemical antagonist tolvaptan. ***p < 0.001, [V4Q5]dDAVP vs. control or [V4Q5]dDAVP plus
tolvaptan. (C) IC50 calculation of cytotoxic agent 5-fluorouracil (5-FU) on exponentially growing CT-26 and Colo-205 CRC
cells. Statistical significance (*p < 0.05) in IC50 calculation studies for 5-FU in CT-26 and Colo-205 was achieved with drug
concentrations ≥ 0.5 or 5 μM, respectively. PBS, phosphate buffered saline. (Continued to the next page)
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testinal tract. After IC50 determination for 5-FU in both CRC
cell lines (Fig. 5C), we explored potential combinational ben-
efits on exponentially growing murine CT-26 and human
Colo-205 cells by adding [V4Q5]dDAVP to sub-IC50 concen-
trations of 5-FU (Fig. 5D). Combined in vitro treatments 
resulted in a synergistic inhibition (CI < 1) (S3 and S4 Tables)
of CRC cell growth in comparison to cytotoxic or [V4Q5]
dDAVP single agent therapies, especially after combining
[V4Q5]dDAVP (1 μM) with 0.5 μM (Fig. 5D, left) or 5 μM 
(Fig. 5D, right) concentrations of 5-FU in the CT-26 or Colo-
205 cell lines, respectively. 
Discussion
As previously described, CRC is a relevant public health
issue, with approximately 50% of patients eventually devel-
oping metastatic disease. To our knowledge this is the first
preclinical report of the antitumor effects of the synthetic
peptide [V4Q5]dDAVP using highly aggressive and metasta-
tic CRC experimental models. In CRC 80% of all metastases
occur in the liver [21,22]. Given the highly relevant biological
functions of the hepatic tissue and their poor prognosis and
elevated incidence, liver lesions associated to CRC attract
particular interest of both clinicians and researchers. In this
work sustained treatment using clinically relevant intra-
venous doses of [V4Q5]dDAVP was capable of impairing
spread and growth of CRC cells in the liver. Moreover,
[V4Q5]dDAVP effects on lung colonization by CRC cells were
also evaluated. Lungs are the second most common site of
seeding of CRC, with pulmonary metastasis occurring in 
approximately 10% of patients who undergo resection of the
primary tumor [21]. In this setting, [V4Q5]dDAVP has also
great clinical applicability given the fact that it was capable
of reducing pulmonary metastatic burden in an experimental
model of massive CRC cell seeding in the lung. 
Numerous studies in CRC patients associate high intratu-
moral vascular density and vascular endothelial growth fac-
tor (VEGF) expression in the primary tumor with an increase
in disease recurrence and metastasis development [23]. In the
present study we assessed the effect of [V4Q5]dDAVP treat-
ment on CRC-associated angiogenesis. After 2 weeks of sus-
tained intravenous treatment using [V4Q5]dDAVP we were
able to reduce by 60% the early vascular development 
induced by Colo-205 cells, a highly aggressive and chemore-
fractory human BRAFV600E positive CRC model. As previ-
ously reported by our group, [V4Q5]dDAVP was able to
impair early angiogenesis induction and reduce vascular
density in hormone-independent breast cancer tumors [15].
[V4Q5]dDAVP, as well as its parental peptide dDAVP, seems
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Fig. 5.  (Continued from the previous page) (D) Addition of [V4Q5]dDAVP to sub-IC50 concentrations of 5-FU enhances in vitro
cytostatic effect on high density AVPR2-expressing CRC cell cultures. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control. #p < 0.05,
##p < 0.01, ###p < 0.001, [V4Q5]dDAVP  plus 5-FU vs. [V4Q5]dDAVP  or 5-FU individual therapies. Results are representative
of at least three independent experiments. Data are presented as mean±standard error of mean. ANOVA plus Dunnet´s test.
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to modulate tumor angiogenesis by inducing the formation
of ANG, a potent angiogenesis inhibitor that is generated by
cancer-mediated proteolysis of plasminogen [3,24]. Addi-
tionally, after analyzing main angiogenic modulators using
mRNA microarrays in AVPR2 expressing breast cancer cells,
dDAVP was also able to modulate key proangiogenic pro-
teins, including a dramatic reduction of VEGF-B and platelet-
derived growth factor, and a complete inhibition of HIF-1A
expression. These results suggest that [V4Q5]dDAVP may
modulate angiogenesis by different mechanisms including
increased production of endogenous angiostatic molecules
and reduction of the expression of different promoters of 
endothelial growth. However, the specific mechanisms 
responsible for [V4Q5]dDAVP antiangiogenic effects remain
to be elucidated.
Despite surgery being the mainstay of treatment of CRC,
recent evidence suggests that surgery may also promote
metastatic relapse through different deleterious mechanisms,
including, but not limited to, tumor cell shedding, immuno-
suppression, increased production of growth factors, and
proangiogenic signaling [25,26]. After analyzing its activity
on CRC metastatic spread and growth, as well as its angio-
static effect, our data suggest that [V4Q5]dDAVP may be 
potentially used to minimize spread or survival of residual
malignant cells perioperatively and during the early postop-
erative period in surgical procedures of colon and other gas-
trointestinal tumors in order to protect the CRC patient from
local or distant recurrence.
Direct effect of [V4Q5]dDAVP on clonogenic or high den-
sity CRC cell cultures was also evaluated. [V4Q5]dDAVP con-
centrations of 1 μM or higher were able to inhibit tumor cell
colony formation, and such cytostatic effects were com-
pletely reverted by AVPR2 chemical blockade using specific
antagonist tolvaptan. In line with these findings, complete
reversal of in vitro [V4Q5]dDAVP activity after AVPR2 chem-
ical blockade was also reported by our group in highly 
aggressive breast cancer cells [15]. Moreover, we recently
showed that after siRNA-mediated knockdown of AVPR2
expression in human lung carcinoma cells, [V4Q5]dDAVP 
antiproliferative effects were significantly attenuated, con-
firming AVPR2-dependency of [V4Q5]dDAVP cytostatic 
action in malignant cells [5,27]. In this experimental setting,
the development of a CRC cell model with AVPR2 gene
knockout or knockdown is highly interesting, and should be
pursued with the aim of corroborating previously described
findings. We previously demonstrated that in vitro antipro-
liferative activity of [V4Q5]dDAVP was associated with par-
tial cell cycle arrest, intracellular cAMP elevation and PKA
activation. Adenylate cyclase/cAMP/PKA axis has been cor-
related in many studies to cancer cell growth inhibition and
antiproliferative signaling events. Increases in cAMP intra-
cellular levels and PKA activation using cAMP analogs or
cAMP elevating agents such as forskolin, can induce growth
arrest in CRC and other tumor cell lines, through different
mechanisms including PKA-dependent inhibition of ERK 
activation or p38 mitogen-activated protein kinase–depen-
dent induction of apoptosis [28,29]. Nevertheless, thorough
studies focusing on intracellular signaling pathways trig-
gered by [V4Q5]dDAVP are necessary to further understand
the implications of vasopressin analogs and their receptors
on CRC biology. 
Given that that therapeutic effects of cytotoxic agents in
CRC are often limited by adverse effects due to low selectiv-
ity, complex dosing and high toxicity, potential benefits of
combining [V4Q5]dDAVP with chemotherapy were explored
in the present study. In this experimental setting [V4Q5]
dDAVP plus 5-FU elicited synergistic cytostatic activity on
rapidly growing CRC cells. Despite it has been previously
reported that other cytostatic and proapoptotic G protein-
coupled receptor ligands can enhance the antiproliferative
activity of 5-FU [30], we are unable to specifically determine
what kind of cross talk between AVPR2 agonists and 5-FU
accounts for the described synergistic effects. In this regard,
proper chemo-therapy regimens for CRC in combination
with [V4Q5]dDAVP remain to be evaluated in preclinical
models with translational relevance.
Taking into account its capacity to modulate tumor cell 
behavior, metastatic spread and tumor-associated angiogen-
esis, selective vasopressin analogs like the novel compound
[V4Q5]dDAVP are interesting candidates for further devel-
opment as adjuvant agents for CRC treatment in combina-
tion to standard chemotherapy or used in a perioperative
setting.
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